Search

Displaying results 2081 - 2090 of 10000 in total
  1. Drug

    Tromethamine

    go.drugbank.com/drugs/DB03754
    ApprovedInvestigational

    It is used in the synthesis of surface-active agents and pharmaceuticals; as an emulsifying agent for cosmetic creams and lotions, mineral oil and paraffin wax emulsions, as a biological buffer, and used … (From Merck, 11th ed; Martindale, The Extra Pharmacopoeia, 30th ed, p1424)

    Mixtures: Sooryehan Hyo Fermented Sun BlockCategories: Compounds used in a research, industrial, or household setting
  2. Drug

    Oxytocin

    go.drugbank.com/drugs/DB00107
    ApprovedInvestigationalVet approved

    Sir Henry H. Dale first identified oxytocin and its uterine contractile properties in 1906. … [A229008] It plays an important role in pair bonding, social cognition and functioning, and even fear conditioning.

    Products: Oxyla 10 IU/mL Injection, Oxytocin Inj 10unit/ml USP
  3. Drug

    Quaratusugene ozeplasmid

    go.drugbank.com/drugs/DB19231
    Investigational

    Quaratusugene ozeplasmid is under investigation in clinical trial NCT05062980 (Quaratusugene Ozeplasmid (Reqorsa) in Combination With Pembrolizumab in Previously Treated Non-small Lung Cancer).

    Synonyms: Dna-lipid complex (dotap/cholesterol) plasmid vector (plj143/pkgb2/tusc2, baylor) expressing the tusc2 gene
  4. Drug

    Dermatophagoides pteronyssinus

    go.drugbank.com/drugs/DB10401
    ApprovedInvestigational

    Dermatophagoides pteronyssinus extracts are sterile solutions used for intradermal testing or subcutaneous immunotherapy. This combination is approved for as a year-round, once-a-day tablet that's dissolved under the tongue as a treatmen...

    Mixtures: Allergenic Extract Mixture Of Standardized Mites (5,000 Au/ml), Allergenic Extract Mixture Of Standardized Mites (15,000 Au/ml)Products: Standardized Mite, Dermatophagoides pteronyssinus, Intradermal, 300 AU per mL, Allergenic Extract Standardized Mite Dp (10,000 Au/ml)
  5. Pathway

    Pyruvate Dehydrogenase Complex Deficiency

    smpdb.ca/view/SMP0000212
    Disease

    PDHA1 encodes the pyruvate dehydrogenase complex (PDC) a critical complex that converts pyruvate from glycolysis to acetyl CoA for the citric acid cycle. … Pyruvate dehydrogenase complex deficiency results from a mutation in the E1-alpha polypeptide gene (PDHA1).

    Drugs: Pyruvic acid · Biotin · Adenosine phosphate · Glutathione · NADH · ATP +13 more
    Enzymes: Dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex, mitochondrial
  6. Pathway

    Mitochondrial Complex II Deficiency

    smpdb.ca/view/SMP0000548
    Disease

    Interestingly, complex II deficiency gene mutation carriers may be at an increased risk for certain cancers. … Because complex II is found in the mitochondria, CII deficiency is technically considered a mitochondrial disease.

    Drugs: Pyruvic acid · Biotin · Succinic acid · NADH · ATP · Magnesium cation +4 more
    Enzymes: Dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex, mitochondrial, Dihydrolipoyllysine-residue succinyltransferase component of 2-oxoglutarate dehydrogenase complex, mitochondrial
  7. Pathway

    Copper gluconate Drug Metabolism

    smpdb.ca/view/SMP0130548
    Metabolic

    Copper gluconate passes through the liver and is then excreted from the body mainly through the kidney. … Copper gluconate is a drug that is not metabolized by the human body as determined by current research and biotransformer analysis.

    Drugs: Copper gluconate
  8. Drug

    Cilgavimab

    go.drugbank.com/drugs/DB16393
    ApprovedInvestigational

    Cilgavimab, in combination with [tixagevimab], was issued an FDA emergency use authorization (EUA) on December 9, 2021, for the pre-exposure prophylaxis of COVID-19 in individuals at increased risk for … [L39411] EVUSHELD was granted marketing authorization by the EMA on March 28, 2022,[L41454] and was approved in Canada soon after, on April 14, 2022.

  9. Drug

    Tixagevimab

    go.drugbank.com/drugs/DB16394
    ApprovedInvestigational

    Tixagevimab, in combination with [cilgavimab], was issued an FDA emergency use authorization (EUA) on December 9, 2021, for the pre-exposure prophylaxis of COVID-19 in individuals at increased risk for … [L39411] EVUSHELD was granted marketing authorization by the EMA on March 28, 2022,[L41454] and was approved in Canada soon after, on April 14, 2022.

  10. Drug

    Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB10788
    ApprovedInvestigational

    Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) is a vaccine that contains inactivated acellular pertussis antigen that is isolated from Bordetella pertussis culture.

    Mixtures: Repevax Injektionssuspension in einer Fertigspritze, -POLIO SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGEProducts: PERTAGEN® SUSPENSION FOR INJECTION 0.5 ML/DOSE